Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Receivables (2016 - 2025)

Celldex Therapeutics has reported Receivables over the past 16 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Receivables at $2.0 million for Q4 2025, up 187.86% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (up 187.86% YoY), and the annual figure for FY2025 was $2.0 million, up 187.86%.
  • Receivables for Q4 2025 was $2.0 million at Celldex Therapeutics, up from $90000.0 in the prior quarter.
  • Over the last five years, Receivables for CLDX hit a ceiling of $2.7 million in Q1 2024 and a floor of $90000.0 in Q2 2025.
  • Median Receivables over the past 5 years was $421500.0 (2021), compared with a mean of $844850.0.
  • Biggest five-year swings in Receivables: surged 1200.0% in 2024 and later plummeted 94.13% in 2025.
  • Celldex Therapeutics' Receivables stood at $172000.0 in 2021, then soared by 101.74% to $347000.0 in 2022, then soared by 657.35% to $2.6 million in 2023, then crashed by 73.36% to $700000.0 in 2024, then skyrocketed by 187.86% to $2.0 million in 2025.
  • The last three reported values for Receivables were $2.0 million (Q4 2025), $90000.0 (Q3 2025), and $90000.0 (Q2 2025) per Business Quant data.